Podcasts about cancer care

A doctor’s choice to walk beside patients through their hardest moments comes from a calling to serve with both skill and heart. Dr. Angela Coscio’s love for people led her from lab research to breast cancer specialization, where she witnesses courage every day. At St. Luke’s, she finds purpose in connecting deeply with patients, guiding them through treatment with compassion and individualized care. Her story reflects teamwork, devotion, and the belief that every medical decision should be a true partnership. Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts. Key Questions Answered Did Dr. Coscio always want to be a doctor? What path did Dr. Coscio take to become a physician? What is the role of an oncologist? How does Dr. Coscio deliver a cancer diagnosis? Why did Dr. Coscio choose oncology as her specialty? What happens at a tumor board? What does being in a comprehensive cancer center like St. Luke’s mean for patients? Are cancer treatment options personalized? How does Dr. Coscio address questions about treatment options, such as chemotherapy vs. hormone therapy? How important is the caregiver's role in cancer treatment and recovery? Does Dr. Coscio encourage second opinions? What advice does Dr. Coscio have for young women facing breast cancer? How does Dr. Coscio support patients in communicating and preparing for doctor appointments? Timestamped Overview 05:06 Interpreter Self-Doubt in Spanish 07:37 Collaborative Patient Care Discussion 10:24 St. Luke's: Team & Care 16:23 Connections in Cancer Care 19:39 Chemotherapy Decision Based on Science 20:45 Engineering Mindset Meets Oncology 25:08 Key Questions for Cancer AppointmentsSee omnystudio.com/listener for privacy information.

Upon receiving a cancer diagnosis, the first priority is to build a clinical treatment plan. But there is another equally...[…]

Upon receiving a cancer diagnosis, the first priority is to build a clinical treatment plan. But there is another equally...

Send us a textJoin us as we return for Part 2 with the superb Dr Alison Berner.It's Transgender Awareness Week and we discuss resources to support patients and clinicians.We discuss OUTpatients and UCATS - UK cancer and transition service.

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. In this episode, Dr Camidge sat down with Mark Socinski, MD, a medical oncologist and the executive medical director of the AdventHealth Cancer Institute in Orlando, Florida. Drs Camidge and Socinski discussed the highlights of Dr Socinski's career trajectory, as well as the personal influences that helped him arrive where he is today. Socinski describes himself as a clinician and clinical investigator with 35 years of focus on lung cancer. His role as executive director of the AdventHealth Cancer Institute involves maintaining an active clinic 1 day a week and dedicating the rest of his time to administrative duties, including recruitment and building infrastructure at the institution. In the interview, Dr Socinski explained that he was influenced to enter a career in medicine because of role of the family practitioner he knew growing up. He went on to receive undergraduate and medical degrees from the University of Vermont in Burlington. After training at Dana-Farber Cancer Institute in Boston, Massachusetts, he began his career in private general oncology practice in Vermont before seeking a more academic, subspecialty environment. He joined the University of North Carolina to concentrate on lung cancer, where he pioneered dose-escalation trials using conformal radiotherapy. Dr Socinski then described his move to the University of Pittsburgh Medical Center in Pennsylvania. There, he became the chair of the lung pathway, which limits treatment options to a single, expert-agreed standard of care based on efficacy, toxicity, and cost, thus reducing treatment heterogeneity and controlling costs. Thereafter, Dr Socinski moved to AdventHealth, attracted by the institution's goal to achieve National Cancer Institute designation and build a major cancer program. Dr Socinski shared that he finds it gratifying to care for patients and lead the development of the institute.

In this deeply inspiring episode of Keeping Abreast, Dr. Jenn Simmons welcomes Dr. Pete Sulack—chiropractor, functional medicine practitioner, and founder of Unhealthy Anonymous—for a powerful conversation about defying the odds after a terminal cancer diagnosis.Dr. Sulack shares how he turned a death sentence into a journey of hope, healing, and renewal. Through faith, nutrition, and lifestyle transformation, he reclaimed his health and now guides others to do the same. Together, he and Dr. Jenn challenge conventional cancer paradigms, exploring how mindset, personalized nutrition, and spiritual alignment can unlock the body's innate capacity to heal.This episode invites listeners to rethink what's possible in cancer recovery and beyond. It's a story of courage, resilience, and faith in both science and spirit—reminding us that health is not something we outsource but something we build from within.In This Episode, You Will Learn:How Dr. Sulack overcame a terminal brain cancer diagnosisWhy functional medicine focuses on healing the whole person, not just treating diseaseThe crucial role of personalized nutrition in recoveryHow food sensitivities and gut health shape overall wellnessWhy conventional medicine often overlooks the importance of dietThe link between faith, mindset, and the body's innate ability to healHow to take proactive responsibility for your healthWhy empowerment and education can change the cancer care paradigm

Send us a textCan spatial biology and multiplex immunofluorescence truly transform how we understand cancer?I went live from the Society for Immunotherapy of Cancer (SITC) 2025 — the 40th Anniversary Meeting to explore how spatial biology, multiplex IF, and digital pathology are coming together to redefine cancer diagnostics, research, and precision medicine.This session kicked off a weekend of cutting-edge discussions with leaders from Hamamatsu (Booth 415) and Biocare Medical (Booth 717) — two companies helping laboratories around the world embrace digital transformation and spatial imaging in oncology.

Never miss another webinar! Signup here: https://imahealth.org/weekly-webinars Learn more: https://imahealth.org/beyond-breakthroughFor more than 50 years, cancer research has chased a single dream: the breakthrough cure that would finally end the disease. But what if that search has taken us down the wrong path?In this week's episode, IMA Senior Fellow Dr. Ryan Cole and IMA Co-Founder Dr. Paul Marik sat down with filmmaker Justin Smith, director of the documentary Beyond Breakthrough, to discuss the growing movement of scientists, doctors, and patients who are redefining what healing really means.Justin shared how creating the film challenged his own assumptions about cancer and how what he discovered may reshape the way you see it too.Together, they explored:How the “breakthrough mindset” has shaped modern cancer researchThe rise of integrative, metabolic, and bioelectric therapiesWhy collaboration across disciplines may hold the key to progressWhat it means to change not just how we treat cancer, but how we understand itThis powerful conversation invited viewers to question long-held beliefs, consider new possibilities, and see cancer care through a more hopeful, holistic lens.• Donate: https://imahealth.org/donate/• Follow: https://imahealth.org/contact/• Webinar: https://imahealth.org/category/weekly-webinars/• Treatment: https://imahealth.org/treatment-protocols/• Medical Disclaimer: https://imahealth.org/about/terms-and-conditions/About IMA (Formerly FLCCC Alliance)The Independent Medical Alliance™ is a nonprofit, 501(c)(3) organization and coalition of physicians, nurses, and healthcare professionals united by a mission to restore trust and transparency in healthcare. The organization's mission is one driven by Honest Medicine™ that prioritizes patients above profits and emphasizes long-term wellness and disease prevention through empowerment of both physicians and their patients. With a focus on evidence-based medicine, informed consent, and systemic reform, IMA is driving a movement to create a more compassionate and effective healthcare system.For more information about the Independent Medical Alliance, visit www.IMAhealth.org

Send us a textAs we approach transgender awareness week we discuss cancer care in the transgender community with the exceptional Dr Alison Berner.1 in 40 people aged under 30 identify as transgender in recent census.How we give support needed and signpost patients can have a huge influence on their experience of care.Alison has done so much work in this area.We learned a lot in this episode and we hope you enjoy!https://outpatients.org.uk/https://www.wearetransplus.co.uk/uk-cancer-and-transition-service/

Jim Foote, CEO and Founder of First Ascent Biomedical a pioneer in functional precision medicine (FPM) that aims to eliminate guesswork from cancer treatment. After losing his son to cancer, Jim left a career in cybersecurity to build a data-driven platform that combines AI, robotics and real-time tumour testing to help doctors choose the right therapy for each patient. In this episode, we explore how FPM differs from traditional genomics-only testing, why tumours can respond differently even with the same patient and how AI can support rather than replace clinicians in treatment decisions. Jim also shares the economic impact of ineffective therapies, the challenges of scaling regulatory innovation in oncology, and why the future of cancer care depends on personalisation at the  cellular level.Timestamps:[00:00:45] What Is Functional Precision Medicine?[00:02:00] Jim's Personal Journey from Tech to Healthcare[00:05:50] Overcoming Regulatory and Systemic Gatekeepers[00:08:13] From Reactive Care to Personalised Treatment[00:09:08] What Lab Findings Reveal about Cancer Cells[00:10:30] Why Genomics Alone Isn't Enough[00:12:03] AI as Decision Support Not a Decision Maker[00:15:55] Cancer in Younger Populations and Misconceptions[00:20:25] Reducing Cost and Waste in Cancer Treatment[00:26:34] What Success Really Means to Jim FooteConnect with Jim - https://www.linkedin.com/in/jim-foote/ Learn more about First Ascent Biomedical - https://www.linkedin.com/company/firstascentbio/ Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalSubscribe to the Podcast

In this first episode of the Unmuted: Equity in Focus

In today's episode, we had the pleasure of speaking with Neal Shore, MD, FACS, about the use of androgen deprivation therapy (ADT) in prostate cancer management. Dr Shore is medical director of the Carolina Urologic Research Center in Myrtle Beach, South Carolina. In our exclusive interview, Dr Shore discussed guidelines for incorporating ADT into prostate cancer clinical practice, toxicities and quality-of-life complications associated with this class of agents that health care providers should be aware of and try to mitigate, and the importance of shared decision-making between members of the multidisciplinary team, as well as patients.

On this edition of The Mark White Show, we're shining a light on the often-overlooked heroes in prostate cancer care, the caregivers. A new national survey reveals that 85% of caregivers attend medical appointments with their loved one and are four times more likely to notice treatment side effects than the patients themselves. Joining me are Dr. Daniel George, Medical Oncologist and Professor at Duke University School of Medicine, and Gina Carithers, President of the Prostate Cancer Foundation. Together, we discuss what this survey uncovers about the day-to-day realities of caregiving, how families can better navigate this journey, and the vital importance of supporting those who give so much of themselves in the process.

In this episode, host Shikha Jain, MD, speaks with Maureen McBeth, PT, MPT, CLT-LANA, about understanding individualized patient experiences with lymphedema, the value of exercise oncology and more. • Welcome to another exciting episode of Oncology Overdrive 0:14 • About McBeth 0:23 • The interview 0:52 • How did you end up in the lymphedema and cancer rehab space? 1:31 • Why is lymphedema such a big topic, especially in the breast cancer space? 3:20 • Jain and McBeth on the complexities of individual lymphedema cases, including studies on lymphatic imaging. 5:25 • Do you feel like there have been advancements in the lymphedema space that can improve our understanding of it? 9:43 • Have stigmas around lymphedema evolved over the years? 12:31 • McBeth on the educational materials available to physicians surrounding cancer-related lymphedema and prospective surveillance. 15:15 • Tell us about ImpediMed and its purpose. 17:06 • How do you incorporate these technologies into the current dialogue about more holistic care? 21:27 • Jain and McBeth on exercise oncology and its impact on overall survival. 24:22 • In ten years, what would you envision as the future of lymphedema and exercise oncology? 29:01 • If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 32:31 • How to contact McBeth 33:33 • Thanks for listening 34:20 Maureen McBeth, PT, MPT, CLT-LANA, is a licensed physical therapist and certified lymphedema therapist with over 25 years of experience in oncology rehabilitation, clinical education, and patient advocacy. She currently serves as senior medical affairs liaison at ImpediMed. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. McBeth can be reached via email mmcbeth@impedimed.com. Learn more about ImpediMed at https://www.impedimed.com/, or follow them on LinkedIn or Instagram @impedimedhealth. References • Pasket ED, et al. J Clin Oncol. 2012;doi:10.1200/JCO.2012.41.8574 • Schmitz KH, et al. J Natl Cancer Inst Monogr. 2025;doi:10.1093/jncimonographs/lgaf007. • Stout NL, et al. Cancer. 2012;doi:10.1002/cncr.27476. Disclosures: Jain and McBeth report no relevant financial disclosures.

In this episode, Ziad Hanhan, MD, hosted a discussion about lung cancer diagnosis, surgical management, and evolving treatment paradigms. Dr Hanhan is a thoracic surgeon at Hackensack Meridian Health, chairman of Surgery at Bayshore Medical Center in Holmdel, New Jersey, and chief of Thoracic Surgery at Riverview Medical Center in Red Bank, New Jersey. He was joined by: Thomas Bauer, MD, the chair of surgery at Jersey Shore University Medical Center in Neptune Township, New Jersey, and Hackensack Meridian Health School of Medicine Rachel NeMoyer, MD, a thoracic surgeon at Hackensack Meridian Health Drs Hanhan, Bauer, and NeMoyer discussed current standards and future directions in thoracic oncology, emphasizing multidisciplinary collaboration and technological innovation. The conversation opened with an overview of lung cancer epidemiology, and the experts noted that this disease remains the leading cause of cancer-related mortality in both men and women. They explained that approximately 90% of lung cancer cases are attributable to tobacco use, making cessation a key preventive measure. They also emphasized that early detection through low-dose CT screening improves outcomes when the disease is identified at an early stage. However, despite these advances, they stated that most lung cancer cases in the United States continue to be diagnosed at stage III or IV, underscoring the need for improved screening adherence. They expanded on current lung cancer screening guidelines and noted that lung cancer often presents with nonspecific symptoms, such as chronic cough or hemoptysis, and that many cases are discovered incidentally on imaging. The surgeons also discussed diagnostic strategies for pulmonary nodules and emphasized a patient-tailored approach that balances diagnostic yield with procedural risk. They also acknowledged that emerging modalities, such as liquid biopsy and breath-based DNA detection, are promising but still investigational. They underscored that frailty assessment remains integral to surgical candidacy determination, with both clinical evaluation and pulmonary function testing guiding decision-making. The team also highlighted the role of multidisciplinary tumor boards in integrating surgical, medical, and radiation oncology perspectives. For early-stage disease, surgery remains the standard, whereas patients with stage III disease typically receive neoadjuvant therapy incorporating immuno-oncology agents. The group also discussed expanding surgical indications in select stage IV cases, reflecting improved survival associated with immunotherapy.

In cancer care, ethical challenges rarely come with easy answers.When should treatment stop? How do teams manage moral distress? And what happens when AI begins to shape clinical decisions?In this episode, Dr. Nico Nortjé, Executive Director for the Center for Clinical Ethics in Cancer Care at MD Anderson Cancer Center, joins host Ginger to explore how oncology professionals navigate those moments when medical facts and human emotions collide.Dr. Nortjé shares what he's learned from leading ethics consultations, guiding care teams through end-of-life discussions, moral distress, and the new ethical questions raised by technology.You'll learn:How to recognize and address moral distress before it leads to burnoutHow ethics consults can turn uncertainty into team alignmentHow to approach treatment-limiting conversations with empathyWhat to consider when AI starts influencing care decisionsListen for a grounded, thoughtful look at what ethics really means in oncology today.

AI is changing everything from policy to the patient room. In this AI&H roundtable, Dr. Doug Flora, a leading voice in oncology innovation, joins Dr. Sanjay Juneja, Dr. Debra Patt, and Mika Newton to tackle what's really holding back AI adoption in healthcare. They explore Medicare's AI prior auth model, the role of clinical decision support, and why strong change management is the linchpin of real progress. Dr. Flora shares leadership lessons and insights from the front lines.

Cancer care should be close to home. It's not just convenient, it's necessary for good patient outcomes. We take a closer look at the growing options in the Northland for patients and their families.

A frightening diagnosis can steal the air from a room. Nicole's story gives it back. From the shock of hearing “breast cancer” to the rhythm of surgery, sixteen chemo infusions and now the daily focus of radiation, she lets us into the real work of getting through it: making plans, asking for help and finding bright spots inside the hard days. As a mother of two and a community leader, she talks candidly about fear, the weight of uncertainty and the simple rituals that brought her peace.Those bright spots include a calm, golden-furred constant: April Sweetie, a therapy dog who turns infusion rooms into gentler spaces. With handler Larry, April visits cancer centers, ICUs and children's hospitals, offering a few minutes of ease to patients and the clinicians who care for them. We explore how therapy animals reduce anxiety and boost morale for healthcare teams who often need support as much as the people they treat. April's own journey from a breeding farm to hospital hallways mirrors the transformation that happens when care becomes truly human.For more content from Centra Health check us out on the following channels.YouTubeFacebookInstagramTwitter

Love the episode? Send us a text!Today's episode is going to challenge how you think about treatment. What if cancer care wasn't one-size-fits-all? What if every decision — from the drugs you take to the supplements you choose — was tailored to your own biology?My guest, Dr. John Oertle, Chief Medical Director at Envita Medical Centers, has spent over 25 years pioneering a truly personalized, integrative approach that merges precision oncology, functional medicine, and technology.We'll explore why some people respond to treatment while others don't, what circulating tumor DNA can tell us about recurrence, and how understanding environmental toxins and genetics can literally change your odds.

This episode of Integrative Cancer Solution features an in-depth conversation with Dr. Christina M. Dieli-Conwright, Associate Professor at Dana Farber Harvard Medical School, who specializes in exercise oncology. Christina begins by sharing her unique career path, transitioning from veterinary medicine to clinical exercise physiology, and ultimately focusing her research on the intersection of exercise and cancer care. Her journey highlights the importance of pursuing one's passions and the impact of interdisciplinary expertise in advancing the field of exercise medicine for cancer patients. A significant portion of the episode centers on the physiological benefits of exercise for those living with cancer. Christina notes that exercise plays a crucial role in improving diverse body systems—from cognitive to immune function—and directly enhances quality of life, helps manage treatment side effects, and may even extend survival. She discusses her involvement in the Department of Nutrition, where she helps craft individualized exercise and nutrition strategies tailored to the unique needs of cancer survivors. The discussion highlights how both aerobic and resistance training are vital components of an optimized exercise program for cancer patients. Christina explains the current guidelines, advocating for at least 150 minutes per week of moderate-to-vigorous aerobic activity, complemented by strength training. She stresses, however, that these recommendations should be adapted to each patient's medical history, treatment stage, and overall health status, with frequent assessments to monitor progress and make necessary adjustments. Christina justifies these approaches with evidence from ongoing clinical trials and epidemiological studies, specifically citing strong data supporting exercise benefits for breast and colon cancer survivors. She also addresses the importance of combining exercise with other interventions, such as fasting, to maximize health outcomes and better manage symptoms like fatigue or hormonal imbalance. Despite the positive trends, Christina is candid about research gaps and the need for more precise, personalized guidelines, particularly for less-studied cancers or unique survivor populations. The episode concludes by empowering cancer survivors to seek out reliable resources for exercise guidance—such as the American Cancer Society and the American College of Sports Medicine—and to maintain motivation through personal support networks and physician recommendations. Christina leaves listeners with the message that consistent, individualized exercise is a transformative tool for surviving and thriving beyond cancer, reinforcing the broader theme that exercise is not only safe but essential for improving both the quality and longevity of life for those affected by cancer.Dr. Christina M. Dieli-Conwright explains how individualized exercise prescriptions can improve cognitive, immune, and overall health outcomes for cancer patients.The episode highlights the importance of both aerobic and resistance training, recommending at least 150 minutes per week of moderate-to-vigorous activity for survivors.Combining exercise with strategies like fasting can help manage fatigue and improve glycemic control during cancer therapy.Clinical evidence shows that exercise during and after cancer treatment is linked to better quality of life and potentially higher survival rates, especially for breast and colon cancers.Reliable resources like the American Cancer Society and American College of Sports Medicine provide support for cancer survivors seeking to tailor exercise to their unique needs.____________________________________If you're ready to expand your mind, elevate your health, and awaken your full potential, subscribe now and join the revolution in conscious living with The Dr. K Show!____________________________________CONNECT WITH DR. K: Website: TheKarlfeldtCenter.comWebsite: TrueHealthShow.comInstagram: https://www.instagram.com/thekarlfeldtcenter/The Science and Spirit of Transformation: A Holistic Guide to Elevating Health, Consciousness, and PurposeURL: https://store.thekarlfeldtcenter.com/products/the-science-and-spirit-of-transformation-Price: $24.99-100% Off Discount Code: DRKSHOWPODCAST_____________________________________The Dr. K Show & Integrative Cancer Solutions were created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com____________________________________If you're ready to expand your mind, elevate your health, and awaken your full potential, subscribe now and join the revolution in conscious living with The Dr. K Show!____________________________________CONNECT WITH DR. K: Website: TheKarlfeldtCenter.comWebsite: TrueHealthShow.comInstagram: https://www.instagram.com/thekarlfeldtcenter/The Science and Spirit of Transformation: A Holistic Guide to Elevating Health, Consciousness, and PurposeURL: https://store.thekarlfeldtcenter.com/products/the-science-and-spirit-of-transformation-Price: $24.99-100% Off Discount Code: DRKSHOWPODCAST_____________________________________The Dr. K Show & Integrative Cancer Solutions were created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

Drs. Ghazal Zandieh, Yash Singh, Thomas DeSilvio, and Brennan Flannery speak with Dr. Joseph Ippolito about how metabolic imaging is transforming cancer diagnosis and treatment through advanced PET and MRI techniques. Together they explore how personalized medicine and sex-specific metabolic differences are reshaping the way radiologists understand and treat glioblastoma. Radiology: Imaging Cancer Journal

Join Dr. Martin in today's episode of The Doctor Is In Podcast.

A tumor that seemed to “smile” back in a flashlight's glare set Jamie Day on a year-long path that tested his body, rewired his priorities, and strengthened every bond that mattered. From the first uneasy swallow after a film festival to the bell that marked the end of treatment, we walk through the raw, funny, and fiercely grateful choices that kept him moving: asking for all the blankets, blasting Mongolian thrash during radiation, and letting two devoted service dogs turn sterile rooms into safe places.HPV-positive squamous cell throat cancer came with good odds and brutal treatment, seven weeks of radiation and chemo that burned, thinned his beard, and made food a battle. Jamie made a decision early: he wouldn't “sad sack” the process. He made the clinic a stage for levity, and the staff met him there. Techs leaned in for the day's soundtrack. Nurses became guides. A nurse advocate unraveled insurance knots at midnight. Front desk faces remembered his name, his jokes, and his dogs. Along the way, he forged symbols to fight by: art of himself on horseback charging the “meatball with tentacles,” a homemade “war hammer,” and the image of two opponents calmly sipping poison until one quits.The through line is simple and strong: choose who you'll be when life breaks, let people help, laugh when you can, and ring the bell for everyone still in the fight. If this story moved you, follow the show, share it with someone who needs a lift, and leave a review with your biggest takeaway so more people can find it.For more content from Centra Health check us out on the following channels.YouTubeFacebookInstagramTwitter

In this episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, speaks with Dr. Ronald Chen, chair of Radiation Oncology and associate director for Community Outreach and Engagement at KU Cancer Center. Dr. Chen shares his personal and professional journey from growing up in Topeka to Harvard and a career on the East Coast and back to Kansas, focusing on his motivation to return home and how his work impacts rural communities. He discusses his efforts in cancer care, telehealth and clinical trials, emphasizing the importance of bringing skills back to Kansas to improve local healthcare. 00:00 Introduction to Bench to Bedside 00:47 Meet Dr. Ron Chen 01:33 Dr. Chen's Educational Journey 03:41 Returning to Kansas 05:40 Advice for Young Kansans 07:19 Midwest Reflections 09:50 Addressing Rural Healthcare Challenges 12:35 Community Engagement and Partnerships 14:46 Balancing Clinical Care and Research 17:02 Future of Cancer Care at KU 19:30 Conclusion and Farewell Links from this Episode: ·       Learn more about Dr. Ronald Chen ·       Read this Q&A with Dr. Chen focused on eliminating health disparities ·       Learn more about community outreach and engagement at KU Cancer Center ·       Read about the Masonic Cancer Alliance To ensure you get our latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center.

Padraig O'Sullivan, Fianna Fail TD for Cork North Central, Pádraig Rice, Social Democrats TD for Cork South-Central, Christina Finn, Political Editor at The Journal and Harry McGee, Political Correspondent with The Irish Times.

This episode is sponsored by IDEXX This podcast episode, hosted by Adam Christman, DVM, MBA, features oncologists Dana Connell, DVM, MPH, DACVIM (Oncology) and Zachary L. Neumann, DVM, MS, DACVIM (Oncology), discussing the significance of early cancer detection in dogs. The conversation focuses on the IDEXX Cancer Dx testing. The doctors explain how the test, which can be included in routine wellness exams, provides rapid results, enabling veterinarians to make timely diagnoses and improve treatment outcomes. They also touch on the importance of the veterinary team in communicating sensitive news to pet owners and the future potential of the test to screen for other types of cancer.

Behind every oncology referral is a patient—and a family—waiting, hoping, and depending on the system to move fast. In this episode, host Dr. Elizabeth Woodcock, Executive Director of the Patient Access Collaborative, is joined by three oncology access leaders: Kristen Thatcher of The James at Ohio State University, Jennifer Kennedy-Stovall of Duke Cancer Institute, and Kate Healy-Levine of Memorial Sloan Kettering Cancer Center. Together, they explore how leading cancer programs are redefining timely access—balancing urgency with empathy, operational efficiency with equity, and data with culture.Tune in to hear how these systems are tackling workforce constraints, leveraging APPs, and redesigning scheduling models to ensure that every patient receives the right care, at the right time.Topics include culture and urgency in access, diagnostic and APP models, template standardization, financial navigation, and equity in oncology care.

Live this week from the ACCC's 42nd National Oncology Conference (NOC), CANCER BUZZ speaks with ACCC Executive Director Meagan O'Neill, MS, who previews the week.  Guest:  Meagan O'Neill, MS Executive Director, Association of Cancer Care Centers   Resources:  ACCC 42nd National Oncology Conference Agenda  

Since 2010, the Association of Cancer Care Centers (ACCC) has produced an annual Trending Now in Cancer Care report, highlighting the biggest challenges, solutions, and opportunities in oncology. In this episode, CANCER BUZZ speaks with Lindsey Causey, DNP, APRN, ANP-BC, AOCNP, nurse practitioner at Cone Health Cancer Center, about part 2 of the 2025 trend report. She shares takeaways from the in-person discussions at the ACCC Annual Meeting & Cancer Center Business Summit (AMCCBS) that informed this report, as well as how she uses the information from ACCC's trend reports at her own cancer center. Part 2 of the 2025 Trending Now in Cancer Care report focuses on payer-driven challenges and solutions, comprehensive cancer care services, research and clinical trials, and mobile screening to engage communities in cancer prevention and education. The full article can be found in Oncology Issues, the official journal of ACCC. Lindsey Causey, DNP, APRN, ANP-BC, AOCNP Nurse Practitioner Cone Health Cancer Center Greensboro, NC “Many patients come into my clinic and they say, I just feel like a piece of me goes to one office, a piece of me goes to another office. I don't want to be seen as pieces of a whole person. I want to be seen as the whole person and know what to do and feel like I have all my answers in one place. “ “[The trend report] really allows you to reflect on what the current state is first and then understand what might need to happen to be able to bring some of these things to fruition.” “Early palliative care is essential, not just because it helps with patients and improving their symptoms and wellbeing, it also increases their survival, but it can also help reduce provider burnout by partnering with palliative care.” Resources: 2025 Trending Now in Cancer Care: Part 1 2025 Trending Now in Cancer Care: Part 2 Archived Reports CANCERBUZZ episode: 2025 Trending Now in Cancer Care: Part 1  

Approximately one in four people will face a cancer diagnosis. For most, the hardest part won't be the treatment itself but the waiting, the 3 AM questions, the logistical maze of care coordination that can mean the difference between hope and despair. Ann Stadjuhar knows this truth from both sides of the stethoscope. When Ann navigated her own cancer diagnosis, she had every advantage: 20 years of healthcare expertise, knowledge of case volumes, connections to top surgeons at Optum. Yet even she found the system overwhelming. Her uncle in rural New Mexico wasn't as fortunate; by the time he reached MD Anderson, inadequate local care had sealed his fate. These parallel experiences crystallized Ann's mission at Reimagine Care: ensuring no one faces cancer alone, regardless of their zip code or insider knowledge. This conversation comes at a critical moment. As cancer increasingly strikes younger populations, with many cancers now appearing in people's 20s and 30s rather than their 50s, we need innovators who understand that technology without empathy is just expensive machinery. Ann represents a new breed of healthcare leaders who see AI not as a replacement for human connection, but as a way to multiply it. "The worst part of cancer is the wait," Ann explains. "We can be there 24/7 to understand whether there may be social determinants of health needs. I need a ride to treatment. I need someone to watch my dog. I have issues paying my electric bill. Sometimes people are honestly more comfortable telling the bot they're having these challenges." After two decades revolutionizing digital health from women's health to pandemic response centers, Ann calls cancer care her "capstone." She's witnessed how the 18-month health system adoption cycle literally costs lives. Now, armed with Meta glasses and AI tools that multiply her capabilities "times four," she's racing against a broken system where your uncle's zip code shouldn't determine whether his cancer stays operable. In this episode of Inspiring Women with Laurie McGraw, discover how one woman's journey through cancer transformed into a mission to democratize access to the kind of insider knowledge that can save lives. From the Cancer X Accelerator to Reimagine Care's AI companion REMI, Ann reveals why the future of cancer care isn't about choosing between humans and machines. It's about creating technology sophisticated enough to know that sometimes, the most advanced intervention is simply helping someone find a dog sitter so they don't miss chemotherapy. For Ann Stadjuhar, reimagining cancer care isn't about replacing human connection. It's about multiplying it. In a healthcare system where staying curious might be the difference between innovation and stagnation, between treatment and tragedy, she's proof that the most powerful technology is the kind that remembers to be human. Key Insights: Why patients confess more to AI than to their doctors, and what that means for care How social determinants of health become matters of life and death in cancer treatment The hidden complexities even healthcare insiders struggle to navigate Why the next generation needs emotional intelligence more than technical skills How one woman's cancer diagnosis became a blueprint for system-wide change About the Guest:  Ann Stadjuhar brings 20+ years of digital health innovation to her role as Chief Growth Officer at Reimagine Care. From launching pharmaceuticals to scaling population health tools, she's run what she calls "the gauntlet" of healthcare transformation. Her personal cancer journey while at Optum revealed the gaps even insiders face, inspiring her mission to ensure 24/7 companionship for every cancer patient through AI-powered human care. Guest & Host Links Connect with Laurie McGraw on LinkedIn Connect with Ann Stadjuhar on LinkedIn Connect with Inspiring Women Browse Episodes | LinkedIn | Instagram | Apple | Spotify

We would love to hear from you! Please share your thoughts or episode ideas at ⁠canceroutloud@cancercare.org⁠ or leave a comment on this episode!Please follow, rate and share Cancer Out Loud to help others find strength and support through our community.SummaryIn this episode, Christina Monaco and Sara Whelan discuss the profound impact of childhood cancer on families, emphasizing the emotional challenges faced by parents and siblings. They explore the importance of resilience in children, the need for community support, and the significance of self-care for caregivers. The conversation highlights the various services available through CancerCare and the necessity of acknowledging the unique experiences of each family affected by childhood cancer.TakeawaysChildhood cancer affects a wide age range, from birth to 17.Each child's experience with cancer is unique and influenced by many factors.Parents often feel guilt and helplessness when their child is diagnosed.Siblings of children with cancer also experience emotional challenges.Asking for help is crucial for families dealing with childhood cancer.Counseling and support groups are vital resources for families.Children with cancer still seek joy and normalcy in their lives.Community support can alleviate some burdens for families.Self-care for caregivers is essential to provide effective support.It's important to acknowledge the emotional impact of childhood cancer on the entire family.

Dr. Hope Rugo and Dr. Giuseppe Curigliano discuss recent developments in the field of bispecific antibodies for hematologic and solid tumors, including strategies to optimize the design and delivery of the immunotherapy. TRANSCRIPT Dr. Hope Rugo: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I am your host, Dr. Hope Rugo. I am the director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center. I am also the editor-in-chief of the Educational Book. Bispecific antibodies represent an innovative and advanced therapeutic platform in hematologic and solid tumors. And today, I am delighted to be joined by Dr. Giuseppe Curigliano to discuss the current landscape of bispecific antibodies and their potential to reshape the future of precision oncology. Dr. Curigliano was the last author of an ASCO Educational Book piece for 2025 titled, "Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances." Dr. Curigliano is a breast medical oncologist and the director of the Early Drug Development Division and chair of the Experimental Therapeutics Program at the European Institute of Oncology in Milan. He is also a full professor of medical oncology at the University of Milan. You can find our disclosures in the transcript of this episode. Dr. Curigliano, Giuseppe, welcome and thanks for being here. Dr. Giuseppe Curigliano: Thanks a lot for the invitation. Dr. Hope Rugo: Giuseppe, I would like to first ask you to provide some context for our listeners on how these novel therapeutics work. And then perhaps you could tell us about recent developments in the field of bispecific antibodies for oncology. We are at a time when antibody-drug conjugates (ADCs) are all the rage and, trying to improve on the targeting of specific antigens, proteins, receptors in the field of oncology is certainly a hot and emerging topic. Dr. Giuseppe Curigliano: So, thanks a lot. I believe really it was very challenging to try to summarize all the bispecific antibodies that are under development in multiple solid tumors. So, the first thing that I would like to highlight is the context and the mechanism of action of bispecific antibodies. Bispecific antibodies represent a groundbreaking advancement in cancer immunotherapy, because these engineered molecules have the unique ability to target and simultaneously bind to two distinct antigens. That is why we call them bispecific. So typically, one antigen is expressed on the tumor cell and the other one is expressed on the immune effectors, like T-cell or natural killer cells. So this dual targeting mechanism offers several key advantages over conventional monoclonal antibodies because you can target at the same time the tumor antigen, downregulating the pathway of proliferation, and you can activate the immune system. So the primary mechanism through which bispecific antibodies exert their therapeutic effects are: First, T-cell redirecting. I mean, many bispecific antibodies are designed to engage tumor-associated antigens like epidermal growth factor receptor, HER2, on the cancer cell and a costimulatory molecule on the surface of T-cell. A typical target antigen on T-cell is CD3. So what does it mean? That you activate the immune system, immune cells will reach the tumor bed, and you have a dual effect. One is downregulating cell proliferation, the other one is activation of the immune system. This is really important in hematological malignancies, where we have a lot of bispecifics already approved, like acute lymphoblastic leukemia or non-Hodgkin lymphoma.  The second, in fact, is the engagement of the tumor microenvironment. So, if you engage immune effector cells like NK cells or macrophages, usually the bispecific antibodies can exploit the immune system's ability to recognize and kill the immune cells, even if there is a lack of optimal antigen presentation.  And finally, the last mechanism of action, this may have a role in the future, maybe in the early cancer setting, is overcoming immune evasion. So bispecific antibodies can overcome some of the immune evasion mechanisms that we see in cancer. For example, bispecific antibodies can target immune checkpoint receptors, like PD-L1 and CTLA-4. Actually, there is a bispecific under development in breast cancer that has a dual targeting on vascular endothelial growth factor receptor and on PD-L1. So you have a dual effect at the same time. So, what is really important, as a comment, is we need to focus first on the optimal format of the bispecific, the optimal half-life, the stability, because of course even if they are very efficient in inducing a response, they may give also a lot of toxicities. So in clinical trials already, we have several bispecifics approved. In solid tumors, very few, specifically amivantamab for non-small cell lung cancer, but we have a pipeline of almost 40 to 50 bispecifics under development in multiple solid tumors, and some of them are in the context of prospective randomized trials. Dr. Hope Rugo: So this is really a fascinating area and it's really exciting to see the expansion of the different targets for bispecific antibodies. One area that has intrigued me also is that some of the bispecifics actually will target different parts of the same receptor or the same protein, but presumably those will be used as a different strategy. It's interesting because we have seen that, for example, in targeting HER2. Dr. Giuseppe Curigliano: Oh, yes, of course. You may consider some bispecifics like margetuximab, I suppose, in which you can target specifically two different epitopes of the same antigen. This is really an example of how a bispecific can potentially be more active and downregulating, let us say, a pathway, by targeting two different domains of a specific target antigen. This is an important point.  Of course, not all the bispecifics work this way, because some of the target antigen may dimerize, and so you have a family of target antigen; an example is epidermal growth factor receptor, in which you have HER1, HER2, HER3, and HER4. So some of them can inhibit the dimerization between one target antigen and the other one, in order to exert a more antiproliferative effect. But to be honest, the new generation of them are more targeting two different antigens, one on the tumor and one on the microenvironment, because according to the clinical data, this is a more efficient way to reduce proliferation and to activate the immune system. Dr. Hope Rugo: Really interesting, and I think it brings us to the next topic, which is really where bispecific antibodies have already shown success, and that is in hematologic malignancies where we have seen very interesting efficacy and these are being used in the clinic already. But the expansion of bispecific antibodies into solid tumors faces some key challenges. It's interesting because the challenges come in different shapes and forms. Tell us about some of those challenges and strategies to optimize bispecific antibody design, delivery, patient selection, and how we are going to use these agents in the right kind of clinical trials. Dr. Giuseppe Curigliano: This is really an excellent question because despite bispecific antibodies having shown a remarkable efficacy in hematological malignancies, their application in solid tumors may have some challenges. The first one is tumor heterogeneity. In hematological malignancy, you have a clear oncogene addiction. Let us say that 90% of the cells may express the same antigen. In solid tumors, it is not the same. Tumor heterogeneity is a typical characteristic of solid tumors, and you have high heterogeneity at the genetic, molecular, and phenotypic levels. So tumor cells can differ significantly from one another, even if within the same tumor. And this heterogeneity sometimes makes it difficult to identify a single target antigen that is universally expressed in an hematological malignancy. So furthermore, sometimes the antigen expressed on a tumor cell can be also present on the normal tissue. And so you may have a cross-targeting. So let's say, if you have a bispecific against epidermal growth factor receptor, this will target the tumor but will target also the skin with a lot of toxicity. The second challenge is the tumor microenvironment. The solid tumor microenvironment is really complex and often immunosuppressive. It is characterized by the presence of immunosuppressor cells like the T regulators, myeloid derived suppressor cells, and of course the extracellular matrix. All these factors hinder immune cell infiltration and also may reduce dramatically the effectiveness of bispecific antibodies. And as you know, there is also an hypoxic condition in the tumor. The other challenge is related to the poor tumor penetration. As you know also with antibody-drug conjugate, only 1 to 3% of the drug will arrive in the tumor bed. Unlike hematological malignancies where tumor cells are dispersed in the blood and easily accessible, the solid tumors have a lot of barriers, and so it means that tumor penetration can be very low. Finally, the vascularity also of the tumor can be different across solid tumors. That is why some bispecifics have a vascular endothelial growth factor receptor or vascular endothelial growth factor as a target. Of course, what do we have to do to overcome these challenges? First, we have to select the optimal antigen. So knowing very well the biology of cancer and the tumor-associated antigens can really select a subgroup of epitopes that are specifically overexpressed in cancer cells. And so we need to design bispecifics according to the tumor type. Second, optimize the antibody format. So there are numerous bispecific antibody formats. We can consider the dual variable domain immunoglobulin, we specified this in our paper. The single chain variable fragments, so FC variable fragments, and the diabodies that can enhance both binding affinity and stability. And finally, the last point, combination therapies. Because bispecific antibodies targeting immune checkpoint, we have many targeting PD-1 or PD-L1 or CTLA-4, combined eventually with other immune checkpoint inhibitors. And so you may have more immunostimulating effect. Dr. Hope Rugo: This is a fascinating field and it is certainly going to go far in the treatment of solid tumors. You know, I think there is some competition with what we have now for antibody-drug conjugates. Do you see that bispecifics will eventually become bispecific ADCs? Are we going to combine these bispecific antibodies with ADCs, with chemotherapy? What is the best combination strategy do you think looking forward? Dr. Giuseppe Curigliano: So, yes, we have a bispecific ADC. We have actually some bispecifics that are conjugated with a payload of chemotherapy. Some others are conjugated with immunoactivation agents like IL-2. One of the most effective strategies for enhancing bispecific activity is the combination therapy. So which type of combination can we do? First, bispecific antibodies plus checkpoint inhibitors. If you combine a bispecific with an immune checkpoint, like anti-PD-1, anti-PD-L1, or anti-CTLA-4, you have more activity because you have activation of T-cells, reduction of immunosuppressive effect, and of course, the capability of this bispecific to potentiate the activity of the immune checkpoint inhibitor. So, in my opinion, in a non-small cell lung cancer with an expression of PD-L1 more than 50%, if you give pembrolizumab plus a bispecific targeting PD-L1, you can really improve both response rate and median progression-free survival.  Another combination is chemotherapy plus bispecific antibodies. Combining chemotherapy with bispecific can enhance the cytotoxic effect because chemotherapy induces immunogenic cell death, and then you boost with a bispecific in order to activate the immune system. Bispecific and CAR T-cells, until now, we believe that these are in competition, but this is not correct. Because CAR T-cells are designed to deliver an activation of the immune system with the same lymphocytes engineered of the patients, with a long-term effect. So I really do not believe that bispecifics are in competition with CAR T-cells because when you have a complete remission induced by CAR T-cell, the effect of this complete remission can last for years. The activity of a bispecific is a little bit different. So there are some studies actually combining CAR T-cells with bispecifics. For example, bispecific antibodies can direct CAR T-cells in the tumor microenvironment, improving their specificity and enhancing their therapeutic effect.  And finally, monoclonal antibody plus bispecific is another next generation activity. Because if you use bispecific antibodies in combination with existing monoclonal antibodies like anti-HER2, you can potentially increase the immune response and enhance tumor cell targeting. In hematological malignancies, this has been already demonstrated and this approach has been particularly effective. Dr. Hope Rugo: That's just so fascinating, the whole idea that we have these monoclonal antibodies and now we are going to add them to bispecifics that we could maybe attach on different toxins to try and improve this, or even give them with different approaches. I suppose giving an ADC with a bispecific would sort of be similar to that idea of giving a monoclonal antibody with the bispecific. So it is certainly intriguing. We also will need to understand the toxicity and cost overall and how we are going to use these, the duration of treatment, the assessment of biomarkers. There are just so many different aspects that still need to be explored.  And then with that idea, can you look ahead five or ten years from now, and tell us how you think bispecific antibodies will shape our next generation cancer therapies, how they will be incorporated into precision oncology, and the new combinations and approaches as we move forward that will help us tailor treatment for patients both with solid tumors and hematologic malignancies? Are we going to be giving these in early-stage disease in solid tumors? So far, the studies are primarily focusing on the metastatic setting, but obviously one of the goals when we have successful treatments is to move them into the early stage setting as quickly as possible. Dr. Giuseppe Curigliano: Let us try to look ahead five years rather than ten years, to be more realistic. So, personally I believe some bispecifics can potentially replace current approaches in specifically T-cell selected population. As we gather more data from ongoing clinical trials and we adopt a deeper understanding of the tumor immuno microenvironment, of course we may have potentially new achievement. A few days ago, we heard that bispecifics in triple negative breast cancer targeting VEGF and PD-L1 demonstrated an improvement in median progression-free survival.  So, how to improve and to impact on clinical practice both in the metastatic and in the early breast cancer setting or solid tumor setting? First, personalized antigen selection. So we need to have the ability to tailor bispecific antibody therapy to the unique tumor profile of individual patients. So the more we understand the biology of cancers, the more we will be able to better target. Second, bispecific antibodies should be combined. I can see in the future a potential trial in which you combine a bispecific anti-PD-L1 and VEGF with immune checkpoint inhibitor selected also to the level of expression of PD-L1, because integration of antibody bispecific with a range of immunotherapies, and this cannot be only immune checkpoint inhibitors, but can be CAR T-cells, oncolytic viruses, also targeted therapy, will likely be a dominant theme in the coming years. This combination will be based on the specific molecular and immuno feature of the cancer of the patient.  Then we need an enhanced delivery system. This is really important because you know now we have a next generation antibody. An example are the bicyclic. So you use FC fragment that are very short, with a low molecular weight, and this short fragment can be bispecific, so can target at the same time a target antigen and improving the immune system. And so the development of this novel delivery system, including also nanoparticles or engineered viral vectors, can enhance the penetration in the tumor bed and the bioavailability of bispecific antibodies. Importantly, we need to reduce toxicity. Until now, bispecifics are very toxic. So the more we are efficient in delivering in the tumor bed, the more we will reduce the risk of toxicity. So it will be mandatory to reduce off-target effects and to minimize toxicity.  And finally, the expansion in new indication. So I really believe you raised an excellent point. We need to design studies in the neoadjuvant setting in order to better understand with multiple biopsies which is the effect on the tumor microenvironment and the tumor itself, and to generate hypotheses for potential trials or in the neoadjuvant setting or in those patients with residual disease.  So, in my opinion, as we refine design, optimize patient selection, and explore new combination, in the future we will have more opportunity to integrate bispecifics in the standard of care. Dr. Hope Rugo: I think it is particularly helpful to hear what we are going to be looking for as we move forward to try and improve efficacy and reduce toxicity. And the ability to engineer these new antibodies and to more specifically target the right proteins and immune effectors is going to be critical, of course, moving forward, as well as individualizing therapy based on a specific tumor biology.  Hearing your insights has been great, and it really has opened up a whole area of insight into the field of bispecifics, together with your excellent contribution to the ASCO Educational Book. Thank you so much for sharing your thoughts and background, as well as what we might see in the future on this podcast today. Dr. Giuseppe Curigliano: Thank you very much for the invitation and for this excellent interview. Dr. Hope Rugo: And thanks to our listeners for joining us today. You will find a link to the Ed Book article we discussed today in the transcript of this episode. It is also, of course, on the ASCO website, as well as on PubMed. Please join us again next month on By the Book for more insightful views on the key issues and innovations that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Follow today's speakers:       Dr. Hope Rugo  @hope.rugo  Dr. Giuseppe Curigliano @curijoey Follow ASCO on social media:       @ASCO on X (formerly Twitter)       ASCO on Bluesky      ASCO on Facebook       ASCO on LinkedIn       Disclosures:      Dr. Hope Rugo:   Honoraria: Mylan/Viatris, Chugai Pharma  Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer  Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx  Dr. Giuseppe Curigliano: Leadership: European Society for Medical Oncology, European Society of Breast Cancer Specialists, ESMO Open, European Society for Medical Oncology Honoraria: Ellipses Pharma Consulting or Advisory Role: Roche/Genentech, Pfizer, Novartis, Lilly, Foundation Medicine, Bristol-Myers Squibb, Samsung, AstraZeneca, Daiichi-Sankyo, Boerigher, GSK, Seattle Genetics, Guardant Health, Veracyte, Celcuity, Hengrui Therapeutics, Menarini, Merck, Exact Sciences, Blueprint Medicines, Gilead Sciences Speakers' Bureau: Roche/Genentech, Novartis, Pfizer, Lilly, Foundation Medicine, Samsung, Daiichi Sankyo, Seagen, Menarini, Gilead Sciences, Exact Sciences Research Funding: Merck Travel, Accommodations, Expenses: Roche/Genentech, Pfizer, Daiichi Sankyo, AstraZeneca      

In this episode of Bladder Cancer Matters, host and survivor Rick Bangs sits down with Dr. Mark Schoenberg—renowned urologist and Chief Medical Officer at UroGen® Pharma—for a wide-ranging conversation about the evolution of bladder cancer research, treatment, and patient advocacy. Dr. Schoenberg shares the story behind BCAN's founding, the early challenges of raising awareness, and the innovations that are reshaping care today, including the development of non-surgical therapies like ZUSDURI™ (mitomycin) for intravesical solution, a prescription medicine used to treat adults with a type of cancer of the lining of the bladder called low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) after you have previously received bladder surgery to remove the tumor and it did not work or is no longer working. From his decades of patient-centered work to his role in pioneering new approaches with UroGen, Dr. Schoenberg offers insights into where the field has been and the promising future ahead. Tune in to hear a fascinating mix of history, science, and hope for patients and families impacted by bladder cancer. Please see the link to the full Prescribing Information on the podcast web page or available at www.zusduri.com.  ZUSDURI Prescribing Information ZUSDURI Patient Information Holzbeierlein J, Bixler BR, Buckley DI, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. J Urol. 2024;10.1097/JU.0000000000003846. ZUSDURI (mitomycin) for intravesical solution is a prescription medicine used to treat adults with a type of cancer of the lining of the bladder called low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) after you have previously received bladder surgery to remove tumor and it did not work or is no longer working. ZUSDURI™ Important Safety Information You should not receive ZUSDURI™ if you have a hole or tear (perforation) of your bladder or if you have had an allergic reaction to mitomycin or to any of the ingredients in ZUSDURI™. Before receiving ZUSDURI™, tell your healthcare provider about all of your medical conditions, including if you: have kidney problems are pregnant or plan to become pregnant. ZUSDURI™ can harm your unborn baby. You should not become pregnant during treatment with ZUSDURI™. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ZUSDURI™. Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with ZUSDURI™ and for 6 months after the last dose. Males being treated with ZUSDURI™: You should use effective birth control (contraception) during treatment with ZUSDURI™ and for 3 months after the last dose. are breastfeeding or plan to breastfeed. It is not known if ZUSDURI™ passes into your breast milk. Do not breastfeed during treatment with ZUSDURI™ and for 1 week after the last dose. How will I receive ZUSDURI™? You will receive your ZUSDURI™ dose from your healthcare provider 1 time a week for 6 weeks into your bladder through a tube called a urinary catheter. It is important that you receive all 6 doses of ZUSDURI™ according to your healthcare provider's instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. During treatment with ZUSDURI™, your healthcare provider may tell you to take additional medicines or change how you take your current medicines. After receiving ZUSDURI™: ZUSDURI™ may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 24 hours. To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water. Clothing that comes in contact with urine should be washed right away and washed separately from other clothing. The most common side effects of ZUSDURI™ include: increased blood creatinine levels, increased blood potassium levels, trouble with urination, decreased red blood cell counts, increase in certain blood liver tests, increased or decreased white blood cell counts, urinary tract infection, blood in your urine. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436. Please see ZUSDURI Full Prescribing Information, including the Patient Information, for additional information.  JELMYTO® Important Safety Information You should not receive JELMYTO® if you have a hole or tear (perforation) of your bladder or upper urinary tract. Before receiving JELMYTO®, tell your healthcare provider about all your medical conditions, including if you are pregnant or plan to become pregnant. JELMYTO® can harm your unborn baby. You should not become pregnant during treatment with JELMYTO®. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO®. Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with JELMYTO® and for 6 months after the last dose. Males being treated with JELMYTO®: If you have a female partner who is able to become pregnant, you should use effective birth control (contraception) during treatment with JELMYTO® and for 3 months after the last dose. are breastfeeding or plan to breastfeed. It is not known if JELMYTO® passes into your breast milk. Do not breastfeed during treatment with JELMYTO® and for 1 week after the last dose. Tell your healthcare provider if you take water pills (diuretic). How will I receive JELMYTO®? Your healthcare provider will tell you to take a medicine called sodium bicarbonate before each JELMYTO® treatment. You will receive your JELMYTO® dose from your healthcare provider 1 time a week for 6 weeks. It is important that you receive all 6 doses of JELMYTO® according to your healthcare provider's instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. Your healthcare provider may recommend up to an additional 11 monthly doses. JELMYTO® is given to your kidney through a tube called a catheter. During treatment with JELMYTO®, your healthcare provider may tell you to take additional medicines or change how you take your current medicines. After receiving JELMYTO®: JELMYTO® may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 6 hours. To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water. Clothing that comes in contact with urine should be washed right away and washed separately from other clothing. JELMYTO® may cause serious side effects, including: Swelling and narrowing of the tube that carries urine from the kidney to the bladder (ureteric obstruction). If you develop swelling and narrowing, and to protect your kidney from damage, your healthcare provider may recommend the placement of a small plastic tube (stent) in the ureter to help the kidney drain. Tell your healthcare provider right away if you develop side pain or fever during treatment with JELMYTO®. Bone marrow problems. JELMYTO® can affect your bone marrow and can cause a decrease in your white blood cell, red blood cell, and platelet counts. Your healthcare provider will do blood tests prior to each treatment to check your blood cell counts during treatment with JELMYTO®. Your healthcare provider may need to temporarily or permanently stop JELMYTO® if you develop bone marrow problems during treatment with JELMYTO®. The most common side effects of JELMYTO® include: urinary tract infection, blood in your urine, side pain, nausea, trouble with urination, kidney problems, vomiting, tiredness, stomach (abdomen) pain. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436. Please click here for JELMYTO® Full Prescribing Information, including the Patient Information, for additional information.  

Dr. Samir Khleif, CEO of biotech company Georgiamune, and medical researcher Georgina Long joined Frances Stead Sellers to discuss how immunotherapy, AI-assisted drug development and novel therapeutic strategies could transform cancer care. Conversation recorded on Wednesday, October 8, 2025. Event sponsored by Pfizer.

Since 2010, the Association of Cancer Care Centers (ACCC) has produced an annual Trending Now in Cancer Care report, highlighting the biggest challenges, solutions, and opportunities in oncology. In this episode, CANCER BUZZ speaks with Calliope Bodenhorn Payne, MHA, virtual care coordinator at Texas Oncology, about part 1 of the 2025 trend report. She shares takeaways from the in-person discussions at the ACCC Annual Meeting & Cancer Center Business Summit (AMCCBS) that informed this report, as well as how these ideas have impacted the standard of care for patients of Texas Oncology.   Part 1 of the 2025 Trending Now in Cancer Care report focuses on AI and BI solutions, navigating tech enablement, strategic partnerships and affiliations, and growth opportunities in oncology. The full article can be found in Oncology Issues, the official journal of ACCC.   Calliope Bodenhorn Payne, MHA Virtual Care Coordinator Texas Oncology   “Technology in health care is changing as rapidly as technology in other sectors, and so we have to be prepared to adopt these new emerging technologies as they're coming along.” “It's so helpful for others to be able to see what steps have been taken by practices all across the United States, and it doesn't matter what size the practice is. It is just a bunch of us who want the best patient care and are looking for innovative ways to make that happen.”   Resources: ·       2025 Trending Now in Cancer Care: Part 1 ·       2025 Trending Now in Cancer Care: Part 2 ·       Archived Reports

Synopsis: Few biotechs can pull off what Syndax Pharmaceuticals has achieved — two first-in-class oncology drug launches, built entirely through strategic in-licensing and disciplined execution. In this episode, host Alok Tayi sits down with Michael Metzger, Chief Executive Officer of Syndax, to explore how the company identified breakthrough assets, advanced them through development, and successfully commercialized them within a span of just a few years. Metzger unpacks Syndax's distinctive model — leveraging external innovation, rapid clinical validation, and precision in go-to-market strategy — to create measurable patient and shareholder value. From the first menin inhibitor approved in acute leukemia to a novel CSF1R antibody reshaping GVHD and fibrosis care, Syndax's portfolio embodies science that scales. The conversation offers an insider's perspective on risk management, deal-making, data-driven decision-making, and why speed to market has become the new differentiator in biotech. A must-listen for investors, executives, and founders navigating the complexities of growth in a capital-intensive industry. Biography: Michael A. Metzger is a seasoned biopharmaceutical executive with extensive leadership experience in company building, operations, and strategic transactions across the life sciences industry. He currently serves as the Chief Executive Officer of Syndax Pharmaceuticals, a publicly traded oncology company, a role he assumed in 2022. Prior to this, Michael served as President and Chief Operating Officer of Syndax from 2015 and has been a member of the company's Board of Directors since 2019. Previously, Michael held leadership roles at Regado Biosciences, Inc, where he served as President and CEO and guided the company through a successful merger with Tobira Therapeutics. He also served as Executive Vice President and COO at Mersana Therapeutics, Inc., where he oversaw key strategic initiatives in ADC development for oncology. Earlier in his career, Michael held senior roles in business development and M&A at Forest Laboratories, LLC, contributing to its transformation ahead of its acquisition by Allergan plc. He also held leadership positions at Onconova Therapeutics, Inc., and was a Managing Director at MESA Partners, Inc., a healthcare-focused venture capital firm. Michael has served on several public and private company boards, including CTI BioPharma Corp., acquired by SOBI AB in 2023, and continues to be active in guiding innovative biotech organizations. Michael holds a B.A. from George Washington University and a M.B.A. in Finance from the NYU Stern School of Business.

In this episode of the Wow Pod, Dr. Kayla Lucas interviews Doris Kun, known as Detoxing Dori on Instagram - who shares her personal journey with thyroid cancer and her exploration of unconventional cancer care. Dori discusses the challenges she faced with the conventional medical system, her extensive research into alternative treatments, and the lifestyle changes she made to support her healing. We all know the common cancer treatments, but what don't we know ?!?Connect with Doris:InstagramSend us a text✨

Dr. Kamal Golla, Vice President of Clinical Technologies and Performance at Evolent, highlights the complexities of cancer care and the need for care navigation to address medical, emotional, financial, and logistical challenges. This comprehensive approach leads to improved treatment adherence and patient satisfaction while reducing emergency room visits and hospitalization. The care team serves as an extension of the medical decision-makers, helping to manage care across multiple specialists, advising on overcoming side effects, and reducing logistical hurdles to ease the burden on physicians and caregivers, ultimately improving patient outcomes. Kamal explains, "Cancer care navigation is really about creating a roadmap for patients. It's making sure they're not left alone to piece together appointments, interpret side effects, or figure out how to pay for medications. The role of a navigator here is really to guide them through the whole journey. That includes the medical components that many folks are familiar with, but also the emotional, financial, and logistical components that come with a cancer diagnosis. The evidence is really clear, given that more than half of emergency department visits and nearly a quarter of hospitalizations related to cancer care are actually avoidable, that responding rapidly to these situations is key." "In our navigation program, we are rooted in patient-centric navigation, meaning we ask them what the transportation difficulties are that they might face. Who is your caregiver and their support? What do you do for work? What are your cultural and religious beliefs? All of those play a big part in dealing with the new diagnosis of cancer. We want all of that information to be able to provide a very personalized journey."  #Evolent #Oncology #CancerCare #CareNavigation #HealthcareInnovation #DigitalHealth #PersonalizedCare #PatientCenteredCare #Evolent #Careology Evolent.com Listen to the podcast here

Dr. Kamal Golla, Vice President of Clinical Technologies and Performance at Evolent, highlights the complexities of cancer care and the need for care navigation to address medical, emotional, financial, and logistical challenges. This comprehensive approach leads to improved treatment adherence and patient satisfaction while reducing emergency room visits and hospitalization. The care team serves as an extension of the medical decision-makers, helping to manage care across multiple specialists, advising on overcoming side effects, and reducing logistical hurdles to ease the burden on physicians and caregivers, ultimately improving patient outcomes. Kamal explains, "Cancer care navigation is really about creating a roadmap for patients. It's making sure they're not left alone to piece together appointments, interpret side effects, or figure out how to pay for medications. The role of a navigator here is really to guide them through the whole journey. That includes the medical components that many folks are familiar with, but also the emotional, financial, and logistical components that come with a cancer diagnosis. The evidence is really clear, given that more than half of emergency department visits and nearly a quarter of hospitalizations related to cancer care are actually avoidable, that responding rapidly to these situations is key." "In our navigation program, we are rooted in patient-centric navigation, meaning we ask them what the transportation difficulties are that they might face. Who is your caregiver and their support? What do you do for work? What are your cultural and religious beliefs? All of those play a big part in dealing with the new diagnosis of cancer. We want all of that information to be able to provide a very personalized journey."  #Evolent #Oncology #CancerCare #CareNavigation #HealthcareInnovation #DigitalHealth #PersonalizedCare #PatientCenteredCare #Evolent #Careology Evolent.com Download the transcript here

It is essential for adolescents and young adults (AYAs) to have a foundation of care prior to discharge after their cancer treatment, and the multidisciplinary care team, including primary care providers (PCPs), must be equipped to support these patients. In this episode, CANCER BUZZ speaks with Scott J. Capozza, PT, MSPT, on his journey navigating care after cancer treatment as a young adult and his ASCO JCO Oncology Practice article, “Patient is Otherwise Healthy.” CANCER BUZZ then speaks with Melody Griffith, MSW, LMSW, Outpatient Adolescent and Young Adult (AYA) Oncology social worker at Mayo Clinic Arizona, on her role in patient navigation and how her department supports AYAs through their entire cancer continuum. CANCER BUZZ concludes with Cathy Lee-Miller, MD, director of AYA Oncology Clinic at the University of Wisconsin Carbone Cancer Center, on their cohort training program preparing PCPs for managing AYA survivorship care.    “The late effects for young adults are very real and a lot of times they are not recognized because we look otherwise healthy on the outside, but that belies what's going on internally.” - Scott J. Capozza, PT, MSPT   “We talk about post-traumatic stress, but also post-traumatic growth and what they bring with them and what they've learned through their process. It's not just the treatment, right? After treatment, there's a lot of years left to live.” - Melody Griffith, MSW, LMSW   “We really try and help empower these patients, particularly AYAs who maybe relied on their parents for their medical care before... We really try to spell that out for people so they can take responsibility and take charge of their own long-term health.” - Cathy Lee-Miller, MD   Scott J. Capozza, PT, MSPT Board Certified Clinical Specialist in Oncologic Physical Therapy  YNHH Outpatient Oncology Rehabilitation Services Smilow Cancer Hospital Adult Cancer Survivorship Clinic New Haven, CT   Melody Griffith, MSW, LMSW Outpatient Adolescent and Young Adult (AYA) Oncology Social Worker Mayo Clinic Arizona Phoenix, AZ   Cathy Lee-Miller, MD Director, AYA Oncology Clinic Associate Professor, Pediatric Hematology/Oncology/Transplant & Cellular Therapy University of Wisconsin Carbone Cancer Center Madison, WI    This podcast is part of the AYA Oncology Screening and Survivorship Services program, made possible through the support from The Arizona Clinical Oncology Society, Indiana Oncology Society, and Wisconsin Association of Hematology and Oncology. Resources: The Arizona Clinical Oncology Society: https://tacos.accc-cancer.org/resources/adolescent-and-young-adult-cancer-resources Indiana Oncology Society: https://inos.accc-cancer.org/resources/aya-cancer-resources Wisconsin Association of Hematology and Oncology: https://waho.accc-cancer.org/resources/adolescent-and-young-adult-cancer-resources

Send us a textWhat if cancer could be detected years before symptoms ever appear? In this episode of Causes or Cures, Dr. Eeks sits down with Dr. Yuxuan Wang, cancer researcher at Johns Hopkins, to discuss her team's promising work on multicancer early detection (MCED) blood tests.These ultra-sensitive sequencing tests can spot tiny fragments of tumor DNA circulating in the blood. In their recent study, the MCED test flagged early cancer signs in 8 out of 26 participants who were later diagnosed — half of them more than three years before their cancer was picked up clinically. While still experimental and not FDA-approved, this research points to a future where cancer screening might extend well beyond mammograms and colonoscopies.In this episode, we cover:Dr. Wang's journey into cancer research and what inspired her focus.What multicancer early detection (MCED) blood tests are and how they work.How the Johns Hopkins study was designed and what the key results showed.Which cancer types were detected and what limitations still exist.Challenges such as false positives, incidental findings, and overtreatment risks.The ethical and practical questions of telling patients they may have cancer years before symptoms.Cost and accessibility concerns: how to make such tests affordable if approved.Next steps toward larger trials, FDA approval, and clinical use.How MCED could change the landscape of cancer screening and prevention in the future.Balancing public enthusiasm, media attention, and scientific caution.This is a fascinating and nuanced conversation about the possibilities, and challenges, of catching cancer earlier than ever before.You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Or Facebook here.Or X.On Youtube.Or TikTok.SUBSCRIBE to her monthly newsletter here! (Now featuring interviews with top experts on health you care about!)Support the show

The cost of cancer care is rising in the U.S. for patients and employers. Learn how those costs are shaping some U.S. employers' health care benefit offerings in this bonus episode. Read Rebecca's post and many other great blog posts at https://blog.ifebp.org/ View the entire Cancer/Oncology Care Strategies: 2025 Pulse Survey report at https://www.ifebp.org/CancerCare2025 International Foundation members get access to all the Foundation's timely research and much more! Learn about membership at https://www.ifebp.org/membership

Editor’s Choice: Integration of self-hypnosis in an enhanced recovery after surgery program in gynecologic oncology – A prospective randomized trial Editorial: Relax - It’s evidence-based: The role of hypnosis in managing post-operative symptoms

Before the Pink Ribbon, talking about breast cancer was taboo. In this episode, we uncover the shocking and inspiring history of breast cancer awareness and the three women who defied a dismissive medical establishment to save millions of lives. Author Judith L. Pearson joins us to discuss her groundbreaking book, "Radical Sisters," revealing how Shirley Temple Black, Rose Kushner, and Evelyn Lauder launched a revolution from their hospital beds and boardrooms. How did a child star, a determined journalist, and a cosmetics mogul tear down the wall of silence and change medicine forever?This deep dive into the evolution of breast cancer advocacy explores the dark ages of treatment and the courageous fight for patient rights. Judith L. Pearson details the brutal radical mastectomy history, specifically the disfiguring Halstead radical mastectomy, a procedure that persisted long after it was proven ineffective. We revisit the pivotal moment of Shirley Temple Black breast cancer advocacy when the beloved star held an unprecedented 1972 press conference from her hospital room, urging women not to be afraid and to perform self-exams. The episode then follows the tenacious activist Rose Kushner and the one-step procedure, a barbaric practice where women went in for a biopsy and woke up with their breasts removed without their consent. Kushner's relentless research and in-your-face advocacy, including a daring appearance on the Donahue show, forced the medical community to confront its paternalism. Finally, we explore the origins of the Evelyn Lauder Pink Ribbon Campaign and her "department store" concept for cancer care at Memorial Sloan Kettering, which was born from the frustrating and fragmented patient experience. This interview sheds light on the complete history of breast cancer awareness, from comparing the fight for funding to the AIDS movement to the discovery of the BRCA gene mutation, revealing a story of courage, tragedy, and ultimate triumph.About Our Guest:Judith L. Pearson is an author and historical biographer specializing in uncovering the stories of overlooked heroes. In her book, "Radical Sisters: The Women Who Pushed for and Paved the Way to Breast Cancer Awareness," she reveals the untold story of the three women whose personal battles and public advocacy transformed medicine and created the modern breast cancer movement.Timestamps / Chapters:(00:00) The Three Women Who Transformed Breast Cancer Awareness(03:31) Shirley Temple Black's Groundbreaking 1972 Announcement(06:05) Rose Kushner's Daring Appearance on the Donahue Show(09:07) The Near-Death Experiences That Shaped the "Radical Sisters"(14:38) How Shirley Temple's Press Conference Changed Everything(19:22) The Brutal History of the Halstead Radical Mastectomy(24:19) Rose Kushner's Fight Against the "One-Step Procedure"(29:56) Evelyn Lauder's Philanthropic Vision Before and After Her Diagnosis(32:28) Learning from the AIDS Movement to Fight for Funding(36:04) Evelyn Lauder's "Department Store" Concept for Cancer Care(40:10) The True Origin Story of the Pink Ribbon Campaign

In this episode, C-Sweet Co-CEOs Dianne Gubin and Beth Hilbing sit down with Margaux Currie, Managing Director at Cigna Healthcare and a stage III breast cancer survivor. Margot shares her powerful journey—from discovering her diagnosis at 39 to transforming her experience into groundbreaking initiatives in oncology, preventative care, and patient advocacy. With candor and wisdom, she discusses self-advocacy, setting boundaries as an executive, leading with vulnerability, and how survivorship reshaped her leadership lens.This episode is a must-listen for leaders navigating health, career, and community impact—proof that resilience and innovation can redefine both business and personal life.Join the community!www.CSweet.org

Send us a textThis week on The Less Stressed Life, we're digging into a bold reframe of cancer: it's not just about the tumor, it's about the terrain. Dr. Nasha Winters and I explore how nervous system state, mitochondrial health, oxygen, light, and circadian rhythm shape resilience and healing. We talk about why standard treatments often fall flat without nervous system regulation, how modern inputs overload our mitochondria, and the simple daily habits that create measurable shifts in terrain.If you've ever wondered why some therapies don't stick—or how breathwork, fasting, light, and minerals could matter just as much as labs and scans—this conversation connects the dots.Find both Dr. Nasha's education courses & books here: https://drnasha.com/books-and-educationKEY TAKEAWAYS:Your nervous system is step zero—nothing works if you're stuck in fight-or-flightMitochondria are the hub of terrain and energy productionOxygen and breathwork are underrated tools in prevention and recoveryDaily rhythm matters: sunrise/sunset light, post-meal walks, and overnight fastingSome “healthy” supplements (iron, calcium, glutathione, methyl donors) can fuel cancer if misusedTiming is everything—especially with red light therapyABOUT GUEST: Dr. Nasha Winters is a global leader in integrative oncology and the author of The Metabolic Approach to Cancer. With decades of experience, she bridges conventional care with metabolic and complementary therapies while making complex science feel accessible and empowering. Her passion lies in helping people understand their bodies, build resilience, and embrace new possibilities for healing. WHERE TO FIND:Website: https://drnasha.com/ Facebook: https://www.instagram.com/drnashawinters/Practitioner Directory: https://www.mtih.org/WHERE TO FIND CHRISTA:Website: https://www.christabiegler.com/Instagram: @anti.inflammatory.nutritionistPodcast Instagram: @lessstressedlifeYouTube: https://www.youtube.com/@lessstressedlifeNUTRITION PHILOSOPHY OF LESS STRESSED LIFE:

In this episode, Talaya sits down with Dr. Fazlur Rahman, a retired oncologist with a remarkable 35-year career spent serving communities in San Angelo, Texas. An author and advocate for patient-centered medicine, Dr. Rahman shares his invaluable insights on what's missing in modern healthcare and how we can bring it back.This is more than a medical conversation; it's a deep exploration of the human side of oncology for anyone navigating cancer, from patients and caregivers to future oncologists. Dr. Rahman shares powerful stories and lessons from a career dedicated to compassionate care.In this episode, we dive into:The Power of Empathy: Why Dr. Rahman believes a compassionate "bedside manner" is as critical as any treatment.Rural Health Barriers: Navigating the unique logistical, cultural, and financial challenges of cancer care in underserved areas.The Patient's Struggle: An honest discussion on the human and financial toll of a cancer diagnosis.Ethical Decisions: Dr. Rahman's perspective on the difficult choices patients and doctors face in modern healthcare.✨Timestamp Highlights:04:34 The Importance of Empathy in Medicine08:05 Dr. Rahman's Books and Writing11:36 Challenges in Cancer Care19:23 Barriers in Rural Cancer Care25:29 Financial and Ethical Struggles42:57 Advice for Future OncologistsTranscript: https://bit.ly/podscript172Connect & Engage with Dr. Rahman:Website: https://fazlurrahmanmd.com/

Send us a textDr. Christy Kesslering, M.D. started out in conventional medicine as a Radiation Oncologist. She received her Bachelor of Science degree from UCLA and attended medical school at Loyola University Chicago-Stritch School of Medicine. She finished her Radiation Oncology Residency at the University of Wisconsin, Madison in 2000 and has been treating patients in the Chicagoland area since that time. She realized that something was missing from conventional medicine and did additional studies to improve outcomes with cancer but also saw many other diseases improve. She has done additional studies in the fields of Functional Medicine, Integrative Medicine, and the Terrain-Theory of cancer. She is a Terrain Certified Practitioner trained by Dr. Nasha Winters and is a founding member of the Society of Metabolic Health Practitioners.  She has been actively incorporating metabolic health practices into the care of oncology patients for many years. She has been named a Top Doctor multiple times by Castle Connelly and Chicago Magazine. She is now focusing her efforts on working with cancer and non-cancer patients to optimize cancer outcomes, improve quality of life, and reverse chronic diseases.  You can find her at: www.Kessrx.com